Date:5/17/2012

ements in this press release. The Company expects to face potential risks and uncertainties related to its ability to, among other things, attract, train, motivate and retain skilled scientists; diversify its customer base and adapt to potential loss of sales to, or significant reduction in orders from, any of its major customers; adapt its business to industry trends, such as fluctuations in the R&D budgets of pharmaceutical and biotechnology industry participants; protect the intellectual property rights of its customers; comply with applicable regulations and industry standards; compete effectively in its industry, which may subject it to increasing pricing pressure and reduce the demand for its services; expand and market its services and manage its growth; and develop and maintain effective internal control over financial reporting; as well as other risks outlined in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company does not undertake any obligation to update any such information, except as required under applicable law.

About Non-GAAP Financial Measures To supplement the Company's consolidated financial results presented in accordance with United States Generally Accepted Accounting Principles ("GAAP"), the Company uses the following non-GAAP financial measures: (1) gross profit, (2) gross margin, (3) profit from operations, (4) operating expenses, (5) operating margin, (6) net income, and (7) diluted earnings per ADS, each of which excludes expenses relating to or the effect of share-based compensation. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. For more information on these non-GAAP financial measures, please see the table captioned "Reconciliatio
'/>"/>

SOURCE ShangPharma Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine technology :

1. ShangPharma to Report First Quarter 2012 Financial Results on May 17, 2012
2. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
3. ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012
4. ShangPharma to Present at Cowens 32nd Annual Health Care Conference
5. ShangPharma Announces Milestone Achievement in Research Partnership with Hengrui
6. ShangPharma Announces Opening of New Facility to Support Lillys Pipeline
7. ShangPharma to Attend Two Upcoming Investor Conferences
8. ShangPharma Announces Third Quarter 2011 Results
9. ShangPharma Purchases Shanghai In-vivo Drug Research Facility from Charles River
10. ShangPharma Corporation Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting
11. ShangPharma Corporation Announces Resignation of a Director